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Autologous bone graft with bone obtained from the iliac
crest has long been used in spinal fusion surgery (1).
Reports of morbidity associated with harvesting iliac crest
bone graft (ICBG) have led to an ongoing quest for bone
graft substitutes. Ever since Urist introduced the use of
bone morphogenic protein (BMP) in 1960, BMPs have
been the subject of debate and various research projects (2).
BMP-2 (Infuse, Medtronics) has been FDA approved
for anterior lumbar interbody fusion. BMP-7 [Osigraft
(OS) and OP1 Putty, Stryker] has only been granted a
Humanitarian exemption for revision posterolateral fusion
in compromised patients.
Delawi et al. recently published a multicenter randomized
trial investigating BMP-7 (OS, Stryker) vs. ICBG (3) for one
level instrumented posterolateral fusion of the lumbar spine
for degenerative or isthmic spondylolisthesis (grade 1 to 2).
The strength of their study comes from the following two
study design features: randomized trial and the use of CT
scan to assess bone bridging. They found that the overall
fusion rate using OS was significantly lower (54%) than
that of ICBG (74%) and that it cannot be recommended for
fusion in posterolateral instrumented fusion. The clinical
outcome (Oswestry disability index, ODI), however, was
comparable in both the groups (84% in OS group compared
to 86% in ICBG group). The OS group had a significantly
higher number of smokers although they did not find this
to be of any significance through a regression analysis.
Vaccaro et al. in their study comparing OP1 Putty
(Stryker) and ICBG for degenerative listhesis, used CT scan
and also radiological angulation/translation criterion to
assess fusion (angulation <5 degree and translation <3 mm
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as fusion success) (4). Using the radiological angulation/
translation criterion, they found similar fusion rates of
69.3% vs. 68.4% for angulation and 74.8% vs. 75.7% for
translation by 36 months. Clinical outcomes at 2 years
using ODI were also comparable; 74.5% in the OP1 group
vs. 75.7% in the ICBG group. The CT scan performed
at 24 months and greater than 36 months showed varying
results. At 2 years, bridging bone at the graft site was
seen in 61.7% in the OP1 group compared to 83.1% in
the ICBG group (P<0.001). At the last follow up (over
36 months), CT showed comparable fusion rates (74.8% in
the OP1 group compared to 77.4% in the ICBG group).
Based on the above observation, assessing bridging fusion
by CT scan at 1 year (as was done in the Delawi study) may
be too early since it seems that the process continues beyond
1 year. The slightly higher fusion rates based on the CT
scans in the study by Vaccaro et al. (61.7%) compared to the
Delawi et al. study (54%) could be due to several reasons
(3,4). The fusion assessment time period was different, as
mentioned above. Only degenerative listhesis was included
in the Vaccaro study while the Delawi study also included
isthmic cases. What was most interesting to note was the
type of BMP-7 used in the studies. Vaccaro et al. used OP1
putty in their study while Delawi et al. used OS. OS is
predominately available in Europe. OP1 Putty (which is the
same as OS in constituent) is available in the United States
but has an additional component, carboxymethylcellulose
(CMC), which may be a factor in enhancing adhesion (5-7).
Currently, there is no literature that directly compares the
effectiveness of OS to OP1 putty (with CMC). Studies have
shown that CMC improves bone formation. Research into
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the effectiveness of OP1 and CMC should be conducted
to further evaluate and validate its effectiveness in fusion
procedures.
Delawi et al. included only grade 1 and 2 listhesis patients
in their study. The results (clinical and radiological) were
not categorized with respect to degenerative or isthmic
type. It would have been interesting to see if the fusion
rates and clinical outcomes differ with respect to the type of
listhesis. This may have been a factor, especially in isthmic
spondylolisthesis where high sheer stress at times requires
robust circumferential fixation techniques.
Iliac crest autografts do have drawbacks with higher rates
of complications including: nerve, arterial and urethral
injury, pelvic fractures, gait disturbances, hematoma,
infection and chronic pain at the harvest site, in addition to
chronic neuralgia (8).
One potential advantage of using OS is avoidance of
morbidity associated with harvesting ICBG, although
Delawi et al. reported no difference in the two groups. We
agree with the Delawi et al. suggestion that the degree of
pain attributed to the donor site is probably over-estimated.
Also, the technique of harvesting autograft also plays a role
with associated morbidity (9,10).
It is important to note that Delawi et al. did not report
any adverse events with the use of BMP-7. Although they
reported that reoperation rates were higher in the OS
group (ten cases compared to two), this was not associated
with use of OS. There has been controversy in the use of
BMP-2. Tannoury et al. explored the complications of bone
morphogenetic proteins in depth, concluding that its use
should be reserved for patients with no other alternative (9).
The Yale University Open Data Access (YODA) studies,
however, indicated the efficacy of BMP-2 to be equivalent
or superior in achieving fusion as compared to autologous
bone graft. BMP-2 is used most often in spine surgery as an
off-label use.
Concerns of carcinogenesis remain at the forefront when
discussing BMP complications, with cancer appearing at
the top of the list of adverse effects; media coverage on
OP1’s rare carcinogenic effects has skewed public opinion
negatively, influencing patients’ decisions about its use (11).
Although previous research may have indicated a
correlation between BMP use and increased incidence for
malignancy, its association has been highly exaggerated
by the media. Current literature suggests no statistical
significance between BMP treatment and cancer (12). Two
recent studies by Dettori et al. and Malham et al., found
no significant association between BMP and the risk of

© Journal of Spine Surgery. All rights reserved.

Drazin et al. BMPs for select spinal surgeries merit further research

cancer (12,13).
New fusion techniques are constantly evolving,
with advancements in technology, biomaterials and
instrumentation that may lead to alternatives for standard
therapies. These alternatives may include off label uses of
medications, such as the current off label use of BMPs in
spine surgery. My personal experience has been that many
of our patients prefer that we use OP1 instead of an iliac
crest autograft because it eliminates the need for them to
undergo an additional incision and procedure with possible
complications.
Delawi et al. did an evidence based study comparing the
effectiveness of BMP-7 use with ICBG, the current gold
standard. Although Delawi et al. could not prove statistical
non-inferiority, this study does suggest areas of further
research. BMPs show promise as a means for interbody and
onlay fusion in spine surgery. Further research studies may
uncover more promising data showing the benefits of BMP
use in selected patients.
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